

The treatment of fresh scaphoid fractures with Pulsed Electromagnetic Fields (PEMF)

Submission date
20/12/2005

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
20/12/2005

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
15/07/2021

Condition category
Injury, Occupational Diseases, Poisoning

☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr B.J. van Wely

Contact details
Veemarkt 129
Nijmegen
Netherlands
6511 ZD
+31 (0)64 176 7608
bobvanwely@yahoo.com

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
The treatment of fresh scaphoid fractures with Pulsed Electromagnetic Fields (PEMF)

Study objectives

The addition of PEMF to cast immobilisation in fresh scaphoid fractures will accelerate consolidation both clinically and radiologically. Possibly the incidence of non-union will be reduced.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local medical ethics committee

Study design

Multicentre, randomised, double blind, placebo controlled, parallel group trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Scaphoid fractures

Interventions

All patients suspected of having a fresh scaphoid fracture will be treated with cast immobilisation. Scaphoid fracture is diagnosed by a combination of physical and radiographic examination. If no apparent fracture line is seen on the initial X-rays, a Technetium scan will be performed (3 - 6 days after injury) to confirm the diagnosis. The PEMF device (supplied by commercial support) will be placed on the cast within one week and will be applied for 24 hours a day continuously. The cast will be a lower arm cast with the first metacarpal bone immobilised. Since the position of the thumb and the hand have no adverse effect on the displacement of the fracture or its consolidation, this neutral plaster is chosen.

Half of the PEMF devices will be disabled at random in the factory. These disabled devices will give outward signs of normal function but will not generate a signal. The investigators will be unaware of the devices functionality. At study completion, device serial numbers will be used to determine which patients received a working device.

Follow up will take place at four, six, twelve and twenty-four weeks after diagnosis of the fractured scaphoid. When the fracture has both clinically and radiologically consolidated the plaster will be removed. If the fracture has not consolidated; a new plaster will be made. Only patients who need immobilisation of the fracture (not consolidated fractures) will have a PEMF device on them, for in clinically and radiographically consolidated patients there is no need for further treatment. If consolidation was established before, it can be checked at later follow up dates if that conclusion wasnt premature. If the fracture is not consolidated after twelve weeks, at physical or radiographic examination, yet the patient has no pain the treatment is finished. If the patient has got pain, he will get a removable splint. All tests will be compared with the opposite unaffected side. In addition to the physical and radiographic examination, patients will be required to fill in two questionnaires:

1. 36-item Short Form health survey (SF-36)
2. The McGill Pain Questionnaire (multidimensional description of the patients feelings of pain)

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Consolidation of the fracture; at 4, 6, 12 and 24 weeks after inclusion the patients will be examined (both radiologically and physically) and will be asked to fill in the questionnaires.

Key secondary outcome(s)

No secondary outcome measures

Completion date

01/09/2007

Eligibility**Key inclusion criteria**

1. Unilateral fresh scaphoid fracture
2. Fracture types: A1, A2, A3, B1, B3 (Herbert Classification)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Pregnancy
2. Presence of life supporting implanted electronical device
3. Fracture of distal radius/ulna, the carpals or metacarpal bones
4. Pre-existing impairment in wrist motion

Date of first enrolment

01/09/2005

Date of final enrolment

01/09/2007

Locations**Countries of recruitment**

Netherlands

Study participating centre

Veemarkt 129

Nijmegen

Netherlands

6511 ZD

Sponsor information

Organisation

Innovative Medical Devices (IMD) B.V. (The Netherlands)

Funder(s)

Funder type

Not defined

Funder Name

Not provided at time of registration

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/10/2012	15/07/2021	Yes	No